线性印迹免疫分析法在真实实验室环境中检测肌炎自身抗体的意大利多中心研究
该研究纳入2024年1至12月意大利八家实验室的1127次肌炎特异性/相关性自身抗体线性印迹免疫分析检测,评估其适宜性、临床一致性与诊断性能。结果显示总体阳性率50.1%,适宜性31.6%,一致性51.3%;在包含临床诊断的666份报告中适宜性53.4%、一致性86.8%,且抗体阳性与IIM诊断显著相关(P<0.001)。
要点
- 总体MSA/MAA阳性率为50.1%(564/1127),但检测适宜性仅31.6%。
- 含临床诊断的报告中一致性达86.8%,IIM患者真阳性率85.4%。
- 抗Jo-1、MDA5、PM-Scl-75/100及Ro52抗体与IIM诊断显著正相关(P<0.001)。
核心结论
- 在疑似IIM的真实临床场景中LIA检测有助于识别特定肌炎抗体,但申请适宜性和临床信息主要影响其诊断性能。
研究设计与样本
- 2024年1至12月意大利八家实验室的多中心研究,共进行1127次MSA/MAA LIA检测(Euroline Myopathies 16 Ags plus cN-1A)。
- 适宜性定义为临床信息与MSA/MAA申请的一致性,临床一致性定义为IIM诊断与LIA结果的一致性,诊断性能定义为LIA确认IIM诊断的可靠性。
主要发现
- 1127次LIA申请中MSA/MAA阳性564次(50.1%),适宜性31.6%,一致性51.3%。
- 1127次申请中666次(59.1%)包含临床诊断,该666份报告的适宜性53.4%、一致性86.8%。
- 666例患者中337例(50.6%)诊断为IIM,329例(49.4%)为非IIM疾病。
- IIM患者中288/337(85.4%)为真阳性MSA/MAA LIA结果,非IIM患者中105/329(31.9%)为假阳性(P<0.001)。
- 抗Jo-1、抗MDA5、抗PM-Scl-75/100及MSA相关抗Ro52抗体观察到显著正优势比(P<0.001)。
关键数值与推荐
- 总体MSA/MAA阳性率50.1%(564/1127),适宜性31.6%,一致性51.3%。
- 含临床诊断的666份报告中适宜性53.4%、一致性86.8%,IIM真阳性率85.4%(288/337),非IIM假阳性率31.9%(105/329),P<0.001。
- 抗Jo-1、抗MDA5、抗PM-Scl-75/100及抗Ro52抗体与IIM诊断正相关(P<0.001)。
临床怎么用
- 申请MSA/MAA LIA时应提供完整临床信息以提高检测适宜性和诊断可靠性。
- LIA结果需结合临床诊断解读,注意非IIM患者中的假阳性可能。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Commercial line immunoassays (LIAs) are used to detect myositis-specific and myositis-associated autoantibodies (MSAs/MAAs) in patients with suspected idiopathic inflammatory myopathy (IIM). However, performance consistency with LIAs remains challenging. We evaluated the appropriateness, clinical consistency, and diagnostic performance of MSA/MAA LIA testing in real-life clinical practice. METHODS: Between January and December 2024, eight Italian laboratories performed 1,127 MSA/MAA LIA determinations (Euroline Myopathies 16 Ags plus cN-1A). LIA appropriateness was defined as concordance between the clinical information provided and the MSA/MAA request; clinical consistency was defined as agreement between the IIM diagnosis and LIA results; and diagnostic performance was defined as the reliability of LIA in confirming an IIM diagnosis. RESULTS: MSA/MAA positivity was observed with 564/1,127 (50.1%) LIA requests. LIA appropriateness and consistency were 31.6% and 51.3%, respectively. Of the 1,127 LIA requests, 666 (59.1%) included a clinical diagnosis. The appropriateness and consistency of the 666 LIA reports were 53.4% and 86.8%, respectively. Among the 666 patients, 337 (50.6%) were diagnosed as having IIM, and 329 (49.4%) were diagnosed as having a non-IIM disease. In patients with IIM, 288/337 (85.4%) received true-positive MSA/MAA LIA results, whereas 105/329 (31.9%) of patients with non-IIM disease received false-positive results (P<0.001). Significant positive odds ratios were observed for anti-Jo-1, anti-MDA5, anti-PM-Scl-75/100, and MSA-associated anti-Ro52 antibodies (P<0.001). CONCLUSIONS: With increasing MSA/MAA requests for suspected IIM, LIA testing can help identify certain antibodies in real-life scenarios. The appropriateness of the request and the clinical information provided mainly influence the LIA diagnostic performance.
引用
- Ghirardello A, Infantino M, Gallo N, et al. Performance of the Line Blot Immunoassay for Detecting Myositis Autoantibodies in Real-Life Laboratory Settings: An Italian Multicenter Study. Ann Lab Med. 2026. PMID: 42394516. doi:10.3343/alm.2026.0024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。